Projected Growth of the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market to Reach $6.09 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the adeno-associated virus (avv) vectors in gene therapy market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market By The End Of 2029?

The adeno-associated virus (avv) vectors in gene therapy market has experienced substantial growth in recent times. It is set to increase from $2.7 billion in 2024 to $3.16 billion in 2025, achieving a compound annual growth rate (CAGR) of 16.7%. Historically, this expansion has been driven by factors such as greater investment in gene therapy research, the growing embrace of gene editing technologies, an uptick in genetic disorders and unaddressed medical requirements, escalating demand for specific targeted therapies, and enhanced cooperation between biotech firms and research institutions.

The adeno-associated virus (AVV) vectors in gene therapy market is anticipated to experience substantial growth in the upcoming years. It is projected to climb to $6.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 17.6%. This expansion during the forecast period is driven by advancements in AAV capsid engineering, a heightened focus on precision medicine, increased investment in genetic research and biotechnology, a rise in gene therapy clinical trials and approvals, and growing demand for personalized treatments. Noteworthy trends for the forecast period include progress in artificial intelligence applications for AAV capsid engineering, the development of hybrid AAV vectors capable of carrying larger genetic payloads, innovations in bispecific antibody-mediated AAV targeting, improvements in scalable AAV production and purification technologies, and the creation of flexible AAV platforms supporting various viral vectors.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

Which Business Drivers Are Underpinning The Growth Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

A rising emphasis on gene-based treatments is anticipated to drive the expansion of adeno-associated virus (AAV) vectors within the gene therapy market moving ahead. Gene-based therapies are medical interventions that alter or manipulate genes to prevent, treat, or cure diseases at the molecular level. Advancements in genetic research are fueling this increasing focus on creating such therapies, as they enhance the precision and effectiveness of gene editing techniques. Adeno-associated virus (AAV) vectors in gene therapy facilitate the development of gene-based therapies by safely and efficiently delivering therapeutic genes into target cells, due to their low immunogenicity and ability to provide long-term gene expression. For example, in 2023, according to IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, global spending on cell and gene therapies reached $5.9 billion, representing a 38% increase from 2022. Therefore, the increasing focus on developing gene-based therapies is propelling the growth of the adeno-associated virus (AAV) vectors market.

What Are The Principal Segment Types In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

How Are Industry Trends Steering The Expansion Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Major companies operating in the adeno-associated virus (AAV) vectors in the gene therapy market are prioritizing sophisticated innovation, such as tailored vector diversity for assay versatility, to enhance target tissue specificity, improve therapeutic efficacy, and expedite the development of customized gene therapies across various indications. Tailored vector diversity for assay versatility refers to employing multiple AAV serotypes or constructs to facilitate various analytical tests and therapeutic applications. As an illustration, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are intended to support the expanding requirements of cell and gene therapy (CGT) development. The portfolio aims to enable a smoother progression from early-stage research to GMP-grade production, contributing to the standardization of processes and the improvement of consistency in viral vector manufacturing. This introduction addresses a significant challenge in advancing CGT programs toward clinical and commercial readiness.

Which Companies Are Contributing Significantly To The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Offers The Most Opportunity For Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Expansion?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2025, By The Business Research Company

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795